Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept in Previously Treated Exudative AMD
NCT01495221Phase 4Completed
- Sponsor
- Vitreous Retina Macula Consultants of New York
- Start
- Dec 2011
- Primary completion
- Mar 2013
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in exudative age-related macular degeneration, sponsored by Vitreous Retina Macula Consultants of New York. Started Dec 2011; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT01495221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01495221.